Table 1 Baseline clinicopathological characteristics of the patients enrolled in this study
Whole study cohort (n = 332) | Training set (n = 168) | Validation set I (n = 72) | Validation set II (n = 92) | |
|---|---|---|---|---|
Age, years | ||||
Median (IQR†) | 63 (56, 72) | 62 (54, 72) | 62 (57, 71) | 66 (56, 75) |
Sex | ||||
Male | 283 (85.2%) | 141 (83.9%) | 63 (87.5%) | 79 (85.9%) |
Female | 49 (14.8%) | 27 (16.1%) | 9 (12.5%) | 13 (14.1%) |
Tumor status | ||||
Primary | 290 (87.3%) | 147 (87.5%) | 57 (79.2%) | 86 (93.5%) |
Recurrent | 42 (12.7%) | 21 (12.5%) | 15 (20.8%) | 6 (6.5%) |
Tumor size | ||||
≤3 cm | 250 (75.3%) | 127 (75.6%) | 51 (70.8%) | 72 (78.3%) |
>3 cm | 82 (24.7%) | 41 (24.4%) | 21 (29.2%) | 20 (21.7%) |
Tumor number | ||||
Single | 202 (60.8%) | 84 (50.0%) | 38 (52.8%) | 80 (87.0%) |
Multiple | 130 (39.2%) | 84 (50.0%) | 34 (47.2%) | 12 (13.0%) |
T stage | ||||
Ta | 194 (58.4%) | 99 (58.9%) | 39 (54.2%) | 56 (60.9%) |
T1 | 138 (41.6%) | 69 (41.1%) | 33 (45.8%) | 36 (39.1%) |
Associated CIS | ||||
No | 320 (96.4%) | 160 (95.2%) | 70 (97.2%) | 90 (97.8%) |
Yes | 12 (3.6%) | 8 (4.8%) | 2 (2.8%) | 2 (2.2%) |
Grade | ||||
Low | 141 (42.5%) | 63 (37.5%) | 22 (30.6%) | 56 (60.9%) |
High | 191 (57.5%) | 105 (62.5%) | 50 (69.4%) | 36 (39.1%) |
CSP3 | ||||
Negative | 190 (57.2%) | 103 (61.3%) | 38 (52.8%) | 49 (53.3%) |
Positive | 142 (42.8%) | 65 (38.7%) | 34 (47.2%) | 43 (46.7%) |
CSP7 | ||||
Negative | 194 (58.4%) | 105 (62.5%) | 40 (55.6%) | 49 (53.3%) |
Positive | 138 (41.6%) | 63 (37.5%) | 32 (44.4%) | 43 (46.7%) |
CSP17 | ||||
Negative | 183 (55.1%) | 95 (56.5%) | 39 (54.2%) | 49 (53.3%) |
Positive | 149 (44.9%) | 73 (43.5%) | 33 (45.8%) | 43 (46.7%) |
GLP-p16 | ||||
Negative | 238 (71.7%) | 134 (79.8%) | 56 (77.8%) | 48 (52.2%) |
Positive | 94 (28.3%) | 34 (20.2%) | 16 (22.2%) | 44 (47.8%) |
No. of positive FISH site | ||||
0 | 135 (40.7%) | 65 (38.7%) | 27 (37.5%) | 43 (46.7%) |
1 | 53 (16.0%) | 37 (22.0%) | 11 (15.3%) | 5 (5.4%) |
2 | 15 (4.5%) | 8 (4.8%) | 5 (6.9%) | 2 (2.2%) |
3 | 76 (22.8%) | 50 (29.7%) | 22 (30.6%) | 4 (4.4%) |
4 | 53 (16.0%) | 8 (4.8%) | 7 (9.7%) | 38 (41.3%) |
FISH test | ||||
Negative | 156 (47.0%) | 82 (48.8%) | 31 (43.1%) | 43 (46.7%) |
Positive | 176 (53.0%) | 86 (51.2%) | 41 (56.9%) | 49 (53.3%) |
Follow Time, months | ||||
Median (IQR) | 31.3 (17.9, 46.6) | 34.8 (25.1, 47.6) | 34.8 (21.9, 39.8) | 23.8 (10.0, 44.1) |
Recurrence | ||||
No | 246 (74.1%) | 122 (72.6%) | 48 (66.7%) | 76 (82.6%) |
Yes | 86 (25.9%) | 46 (27.4%) | 24 (33.3%) | 16 (17.4%) |